PUNE, India, April 19, 2017 /PRNewswire-iReach/ -- The market report Premature Labor (Tocolysis) Pipeline Review, H1 2017, provides an overview of the Premature Labor (Tocolysis) (Women's Health) pipeline landscape. Report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics.
Browse 18 Tables and 9 Figures, 5 Company Profiles, spread across 49 pages is available at http://www.reportsnreports.com/reports/944626-premature-labor-tocolysis-pipeline-review-h1-2017.html.
The Premature Labor (Tocolysis) Companies Involved in Therapeutics Development are AMAG Pharmaceuticals Inc, GlaxoSmithKline Plc, Juniper Pharmaceuticals Inc, Kissei Pharmaceutical Co Ltd, Lipocine Inc, ObsEva SA. The Premature Labor (Tocolysis) (Women's Health) pipeline guide reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Premature Labor (Tocolysis) Drug Profiles are bedoradrine sulfate, hydroxyprogesterone caproate, OBE-022, progesterone and retosiban.
Premature Labor (Tocolysis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Order a Copy of Report at http://www.reportsnreports.com/purchase.aspx?name=944626.
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Premature Labor (Tocolysis) (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Premature Labor (Tocolysis) Overview
Premature Labor (Tocolysis) Therapeutics Development
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Premature Labor (Tocolysis) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Media Contact: Ritesh Tiwari, ReportsnReports.com, + 1 888 391 5441, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com